Feasibility study on the treatment for brain metastases of lung cancer via intensity-modulated radiotherapy combined with simultaneous integrated boost
10.19401/j.cnki.1007-3639.2016.08.008
- VernacularTitle:适形调强放疗同期整合瘤床推量治疗肺癌脑转移瘤的可行性研究
- Author:
Xuebin CHENG
;
Lin XIAO
- Publication Type:Journal Article
- Keywords:
Intensity-modulated radiotherapy;
Lung cancer;
Brain metastasis;
Simultaneous integrated boost
- From:
China Oncology
2016;26(8):687-692
- CountryChina
- Language:Chinese
-
Abstract:
Background and purpose:The incidence of lung cancer with brain metastasis tends to go up. The technique of intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) for tumor bed is a new treatment choice for patients with brain metastasis. This study aimed to investigate the feasibility of IMRT combined with SIB for tumor bed in the treatment of brain metastases of lung cancer by exploring its short-term clinical effect and treatment-related toxicities.Methods:Thirty-two patients who were diagnosed as having lung cancer with 1-4 brain metastases were prospectively collected. All the brain metastases were treated with whole brain 5 ifelds IMRT (40 Gy/20 f) combined with SIB (50 Gy/20 f). The dosage distribution within the target volume and dose-volume histogram were evaluated. Meanwhile, the overall response rate of radiotherapy, thelocal tumor control rate, 1-year survival rate, treatment-related acute and late toxicities were also calculated.Results:All patients were treated with IMRT successfully. The rate of Grade 2 vomitting, nausea, epilepsy was 9.4%, 15.6%, and 12.5%, respectively. Two cases had Grade 2 cognitive impairment, 4 cases had Grade 2 memory injury, and 2 cases had Grade 3 memory injury. There were no any Grade 4 events of acute and late toxicities. The overall response rate of radiotherapy was 71.9%. The local tumor control rate was 96.9%, and 1-year survival rate was 44%.Conclusion:It is feasible to use 5 ifelds IMRT (40 Gy/20 f) combined with SIB (boosting 10 Gy, i.e. total dose 50 Gy/20 f) for the treatment of brain metastases of lung cancer.